Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Transformative nanotechnology drug delivery platform enabling eradication of micrometastases in ovarian cancer

Objetivo

NaDeNo is a Norwegian biopharma company advancing a proprietary nanotechnology platform to transform local drug delivery and retention at disease sites. Originating from SINTEF, Europe’s leading research institute, NaDeNo builds on decades of nanotherapeutic expertise. Its lead program, PACAB-002, is a novel nanoformulation of cabazitaxel designed for intraperitoneal treatment of micrometastases in high-grade serous ovarian cancer (HGSOC)—a major unmet need where systemic therapies fail due to poor vascularization. By encapsulating the drug in poly(alkyl cyanoacrylate) (PACA) nanoparticles, PACAB-002 achieves efficient transport, tumour adhesion, and sustained local release, overcoming limitations of free drugs and conventional intraperitoneal formulations. Preclinical studies demonstrated 100% survival and a 97% tumour weight reduction compared to non-encapsulated cabazitaxel, highlighting its potential to reduce relapse rates and improve outcomes.

Our platform brings together multiple innovations that redefine how drugs can be formulated and delivered: 1) a unique ability to solubilize and encapsulate poorly soluble drugs with novel chemistries; 2) a proprietary one-step, low-cost, scalable manufacturing process; and 3) distinctive mode of action enabling receptor-independent tissue accumulation and retention. Beyond PACAB-002, the platform could unlock new therapeutic opportunities by reviving potent but poorly soluble compounds, for next-generation oncology and other hard-to-formulate treatments.

NaDeNo plans to initiate a phase 1/2a trial for PACAB-002 in 2H 2026, aiming for market entry in 2033. Financial projections model €4.2B lifetime revenues, with royalties reinvested into platform expansion. To achieve this, NaDeNo seeks EIC Accelerator support (€2.5M grant, €7.5M equity) to advance PACAB-002 into clinical development and establish a new standard of care for ovarian cancer.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIC-2025-ACCELERATOR-02

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

NADENO NANOSCIENCE AS
Aportación neta de la UEn
€ 2 499 999,00
Dirección
PROFESSOR BROCHS GATE 16
7030 TRONDHEIM
Noruega
Pyme
Sí
Región
Norge Trøndelag Trøndelag
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos